Patents Examined by Stephanie K Springer
  • Patent number: 10413517
    Abstract: Methods and compositions which include or include the administration of a hydrophobic drug, prodrug thereof, salt thereof, isoform thereof, or a combination thereof; cyclodextrin, prodrug thereof, salt thereof, or a combination thereof; polyethylene glycol, propylene glycol, or combination thereof; and optionally, a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: September 17, 2019
    Assignee: UNIVERSITY OF NOTRE DAME DU LAC
    Inventors: Kasturi Haldar, Md. Suhail Alam
  • Patent number: 10405538
    Abstract: Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: September 10, 2019
    Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI
    Inventors: Yi Zheng, Jose Cancelas
  • Patent number: 10406133
    Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: September 10, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
  • Patent number: 10357486
    Abstract: This invention relates to the treatment of varying degrees of cognitive impairment associated with, for example, aging, Alzheimer's disease, schizophrenia with low dose administration of a PDE4 inhibitor, specifically roflumilast.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: July 23, 2019
    Assignee: UNIVERSITEIT MAASTRICHT
    Inventors: Jos Prickaerts, Marlies van Duinen, Anke Sambeth, Arjan Blokland
  • Patent number: 10351517
    Abstract: This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: July 16, 2019
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Abdallah Ahnaou, Wilhelmus H. I. M. Drinkenburg, Joseph Palumbo, Jonathan Sporn
  • Patent number: 10336757
    Abstract: Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are other wise delivered to the brain.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: July 2, 2019
    Assignees: Sloan-Kettering Institute for Cancer Research, The Rockefeller University
    Inventors: Gabriela Chiosis, Paul Greengard, Fei Dou, Wenjie Luo, Huazhong He, Danuta Zatorska
  • Patent number: 10300055
    Abstract: Methods are provided for the treatment of Parkinson's disease (PD) in patients bearing mutations in the LRRK2 gene. A therapeutically effective amount of piperazine derivative compounds are employed to inhibit the biological activity of ArfGAP1, inhibition that counteracts the deleterious effects of mutations in, or increased expression of, the LRRK2 protein.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: May 28, 2019
    Assignee: DALHOUSIE UNIVERSITY
    Inventors: Michel Roberge, Chris McMaster, Carla Zimmerman, Pak Poon
  • Patent number: 10251909
    Abstract: The present invention includes compositions and methods for using a single pharmaceutical preparation of KMgCit is a convenient surrogate or to support the DASH diet in lowering blood pressure among patients with essential hypertension. Support is provided by potassium, magnesium and alkali, which overcome the underlying physiological-biochemical disturbances of essential hypertension, such as salt sensitivity, insulin resistance, low urinary pH, low serum magnesium and renal leak of calcium. Positive effects of KMgCitrate disclosed in normal subjects and patients with stones, provides assurance that KMgCitrate should ameliorate the above physiological-biochemical disturbances and associated disorders in patients with essential hypertension.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: April 9, 2019
    Assignee: Board of Regents, the University of Texas System
    Inventor: Charles Y. C. Pak
  • Patent number: 10213420
    Abstract: Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: February 26, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventor: George D. Hartman
  • Patent number: 10214491
    Abstract: The invention presents methods of identifying small molecule compounds that are activators of tumor suppressor protein p53 pathway, and its associated family members p63 and p73, function. The invention is further drawn to methods of killing tumor cells and treating cancers or other conditions requiring activation of the p53 family member pathways and DNA damage response pathways with the small molecules.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: February 26, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Marikki Laiho, Karita Peltonen
  • Patent number: 10208039
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer, melanoma, and the like.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: February 19, 2019
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Amogh Boloor, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Patent number: 10208007
    Abstract: Compound of formula X wherein P1 is a fused-ring system comprising one 6-membered and two 5-membered rings; v indicates an S or R configuration; or individual isomers or pharmaceutically acceptable salts thereof, or mixtures thereof, in the preparation of an active agent for preventing or inhibiting cell proliferation or for inducing cell death.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: February 19, 2019
    Inventors: Yoram Kapulnik, Hinanit Koltai, Ronit Yarden, Cristina Prandi
  • Patent number: 10202381
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer, melanoma, and the like.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: February 12, 2019
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Amogh Boloor, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Patent number: 10179789
    Abstract: The invention provides compounds of formula I: wherein A, B, X, and Y have any of the values defined in the specification, as well as pharmaceutical compositions comprising such compounds, processes for preparing such compounds, and therapeutic methods for treating cancer and other topoisomerase mediated conditions.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: January 15, 2019
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Edmond J. LaVoie, Wei Feng, Leroy F. Liu
  • Patent number: 10154987
    Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: December 18, 2018
    Assignee: Silvergate Pharmaceuticals, Inc.
    Inventors: Gerold L. Mosher, David W. Miles
  • Patent number: 10137120
    Abstract: Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: November 27, 2018
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Junfa Fan, Pingchen Fan, Antoni Krasinski, Lianfa Li, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Patent number: 10138208
    Abstract: Compositions that modulate the activity of signal transducer and activator of transcription-3 (STAT3) activity as well as their methods of use, such as treatment and imaging are provided. Compositions contain small molecules such as substituted pyrazoles and are useful in treatment of diseases related to the activity of STAT3 including, for example, cancer and other diseases.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: November 27, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: David J. Daniels, Ian F. Parney, Timothy E. Peterson
  • Patent number: 10130628
    Abstract: This disclosure provides a technology for managing the sensation of pain in a subject in need thereof. Treatment methods according to this invention include administering to the subject a formulation that contains an effective amount of (4-[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone).
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: November 20, 2018
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH ON AGING, THE JOHNS HOPKINS UNIVERSITY, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Nathaniel David, Albert Davalos, Remi-Martin Laberge, Judith Campisi, Marco Demaria, Alain Vasserot, Chaekyu Kim, Okhee Jeon, Jennifer Elisseeff, James L. Kirkland, Tamar Tchkonia, Yi Zhu
  • Patent number: 10130636
    Abstract: A tablet including high dosage of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one camsylate salt has been disclosed.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: November 20, 2018
    Assignee: Clovis Oncology, Inc.
    Inventor: Jeffrey Etter
  • Patent number: 10117846
    Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: November 6, 2018
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame